(Q46867668)

26 December 2017

title

In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006). (English)

1 reference

26 December 2017

methicillin-resistant Staphylococcus aureus

main subject

0 references

Staphylococcus aureus

1 reference

Kazuo Hatano

1

1 reference

26 December 2017

Kaoru Matsuzaki

2

1 reference

26 December 2017

Yumie Sato

3

1 reference

26 December 2017

Intetsu Kobayashi

4

1 reference

26 December 2017

Keizo Yamaguchi

5

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

The Journal of Antibiotics

published in

1 reference

26 December 2017

volume

60

1 reference

26 December 2017

issue

11

1 reference

26 December 2017

page(s)

709-712

1 reference

26 December 2017

Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Epidemiological Profile of Linezolid‐Resistant Coagulase‐Negative Staphylococci

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

1 reference

https://api.crossref.org/works/10.1038%2FJA.2007.91

7 January 2021

Identifiers

DOI

10.1038/JA.2007.91

1 reference

26 December 2017

1 reference

26 December 2017